Atypical hemolytic uremic syndrome genetic testing can help healthcare professionals investigate whether inherited changes in complement system genes may contribute to aHUS. The condition is a rare form of thrombotic microangiopathy that can affect the kidneys, blood cells, and other organs. Genetic testing does not by itself establish.
Atypical hemolytic uremic syndrome, commonly called aHUS, is a rare disorder involving abnormal activation of the complement system. This can contribute to damage affecting small blood vessels and may result in thrombocytopenia, hemolytic anemia, and kidney injury. Genetic testing is one component of a broader diagnostic evaluation. It may be considered when clinicians suspect complement-mediated disease, particularly after other potential causes of thrombotic microangiopathy have been investigated.
Genetic testing generally examines genes associated with regulation or activation of the complement system. Variants in several genes have been associated with susceptibility to aHUS, although the presence of a genetic variant does not necessarily mean that a person will develop the condition. Some individuals with clinically diagnosed aHUS may also have no identifiable disease associated genetic variant.
Testing may involve a blood or saliva sample, depending on the laboratory and testing method. Results require careful interpretation because genetic findings can have different levels of clinical significance.
Common considerations include:
Pathogenic or likely pathogenic variants: These may provide evidence of an inherited predisposition associated with complement dysfunction.
Variants of uncertain significance: Their relationship to disease is not established and they generally should not be treated as definitive evidence of aHUS.
Negative results: No relevant variant is identified, but this does not necessarily exclude aHUS.
Complement related genes: Testing may examine several genes because aHUS can involve different genetic pathways.
Family evaluation: In selected circumstances, testing relatives may help clarify inherited genetic findings and potential susceptibility.
Genetic test results should be considered together with the individual's clinical presentation and laboratory findings. Tests commonly used during evaluation of suspected aHUS may include blood counts, markers of hemolysis, kidney function measurements, complement assessments, and investigations for other causes of thrombotic microangiopathy. Genetic testing is therefore not a standalone diagnostic test.
Genetic counseling can be useful before and after testing, particularly when a potentially significant inherited variant is identified. Counseling can help explain what the result means, what it does not establish, and whether testing may be appropriate for family members.
Important aspects of interpretation include:
Clinical correlation: Genetic findings should be compared with symptoms, laboratory results, and medical history.
Inheritance patterns: Some complement-related variants may be inherited, while other cases can involve newly occurring genetic changes.
Incomplete penetrance: Carrying a disease associated variant does not always mean that an individual will develop aHUS.
Family implications: A confirmed inherited variant may have relevance for biological relatives.
Ongoing interpretation: Classification of genetic variants can change as scientific evidence develops.
atypical hemolytic uremic syndrome genetic testing can provide useful information about possible genetic susceptibility to complement-mediated disease. However, genetic results need careful interpretation and should not be considered independently of clinical and laboratory evidence. A comprehensive evaluation can help distinguish aHUS from other causes of thrombotic microangiopathy and provide a clearer understanding of the individual's circumstances. Genetic counseling may also help patients and families understand testing results and their potential implications.